An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone

Clinical Laboratory

Volumn 50, Issue 5-6, 2004, Pages 279-289

  Cloos, Paul A C ^a   Lyubimova, Nina ^b   Solberg, Helene ^a   Qvist, Per ^a   Christiansen, Claus ^c   Byrjalsen, Inger ^a   Christgau, Stephan ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

CTX; CTX; Bone metastases; Breast cancer; Crosslinks; CTX; Isomerization; Resoption markers

Indexed keywords

COLLAGEN TYPE 1; TUMOR MARKER;

ADULT; ALPHA CHAIN; ARTICLE; BETA CHAIN; BONE DEFECT; BONE METASTASIS; BREAST CANCER; CANCER INVASION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CROSS LINKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; OSTEOLYSIS; POSTMENOPAUSE; PROTEIN URINE LEVEL; STATISTICAL ANALYSIS; URINALYSIS; URINARY EXCRETION;

BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; COLLAGEN; COLLAGEN TYPE I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; PEPTIDE FRAGMENTS;

EID: 3042730990     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lipton A. Bisphosphonates and breast carcinoma. Cancer 1997; 80(8 Suppl): 1668-1673.
2. Ryberg M, Nielsen D, Osterlind K, Skovsgaard T, Dombernowsky P. Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann. Oncol. 2001; 12: 81-87.
3. Cloos PAC and Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized. A biological clock of protein ageing with clinical potential. Biochem. J. 2000; 345: 473-480.
4. Cloos PAC, Fledelius C, Christgau S, Christiansen C, Engsig M, Delmas P, Body JJ, Garnero P. Investigation of bone disease using isomerized and racemized fragments of type I collagen. Calcif Tissue Int. 2003; 72: 8-17.
5. Garnero P, Fledelius C, Gineyts E, Serre CM, Vignot E and Delmas PD. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone. J Bone Miner Res. 1997; 12: 1407-1415.
6. Bonde M, Fledelius C, Qvist P and Christiansen C. Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption. Clin Chem. 1996; 42: 1630-1644.
7. Fledelius C, Johnsen AH, Cloos PAC, Bonde M, Qvist P. Characterisation of urinary degradation products derived from type I collagen. J Biol Chem. 1997; 272: 9755-9763.
8. Fledelius C, Kolding I, Qvist P, Bonde M, Hassager C, Reginster JY et al. Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type 1 collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA. Scand J Clin Lab Investig. 1996; 57: 73-83.
9. Rosenqvist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, and Christiansen C. Serum CrossLaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 1998; 44: 2281-2289.
10. Cloos PAC, Christgau S, Lyubimova N, Body JJ, Qvist P, Christiansen C 2003 Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments. Breast Cancer Res. 2003; 5(4): R103-9.
11. Kearny JF, Radbruch A, Liesegang B, Rajewsky K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell-lines. J Immunol. 1979; 123: 1548-50.
12. Knott L and Bailey AJ. Collagen cross-links in mineralising tissues: A review of their chemistry, function and clinical relevance. Bone 1998; 22: 181-187.
13. Coleman R, Rubens R. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987; 55: 61-66.
14. Galakso CSB, Burn JI. Hypercalcemia in patients with advanced mammary cancer. Br Med J. 1971; 3: 573-577.
15. Wedin R. Surgical treatment for pathological fracture. Acta Orthop Scand.2001; 72: 1-29.
16. Wedin R, Bauer HC, Rutqvist LE. Surgical treatment for skeletal breast cancer metastases: a population based study of 641 patients. Cancer 2001; 92: 257-262.
17. Dillman RO and Chico S. Radiology test after a new diagnosis of breast cancer. Eff. Clin. Pract. 2000; 3: 1-6.
18. Vinholes JJF, Purohit OP, Abbey ME et al. Relationship between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol. 1997; 8: 1243-1250.
19. Lipton A, Demers L, Curley E et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer. 1998; 34: 2021-2026.
20. Jagdev SP, Purohit OP, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 2001; 12: 1433-1438.
21. Koizumi M, Takahashi S, Ogata E. Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer. Breast Cancer 2003; 10: 21-27.
22. Bajetta E, Martinetti A, Zilembo N, Pozzi P, La Torre I, Ferrari L, Seregni E, Longarini R, Salvucci G, Bombardieri E. Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Ann Oncol. 2002; 13: 1059-1066.
23. Hou MF, Lin SB, Yuan SS, Tsai LY, Tsai SM, Hsieh JS, Huang TJ. Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients. Ann Clin Lab Sci. 2003; 33: 55-61.